Stockreport

Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission [Yahoo! Finance]

Century Therapeutics, Inc.  (IPSC) 
PDF increased its price target for Century Therapeutics to $4 from $2 with an Overweight rating, citing the company's plan to submit an IND for CNTY-813 this year and delive [Read more]